Structure-based approaches to inhibition of erbB receptors with peptide mimetics
The epidermal growth factor (EGF) family of tyrosine kinase receptors (erbB receptors) are expressed at high levels in a wide variety of human cancers and have been associated with various features of advanced disease and poor prognosis. Therapeutic blockade of erbB signaling is a novel approach to the treatment of human tumors that could offer a noncytotoxic alternative to cancer treatment. A number of monoclonal antibodies (MAbs) directed against erbB receptors have been developed and demonstrated promising therapeutic results. We have designed small-molecule peptide mimetics of an anti-erbB rhu MAb 4D5 that can mimic structural and functional properties of the parental antibody. An alternative structure-based strategy of erbB receptor blockade with peptide mimetics by targeting receptor dimerization interfaces is also described.
Key WordsAntibodies Inhibitors HER2 Disabling erbB receptor ensembles Structure-based design Peptidomimetics
Unable to display preview. Download preview PDF.
- 12.Xu FJ, Boyer CM, Bae DS, Wu S, Greenwald M, O'Briant K, et al.: The tyrosine kinase activity of the c-erbb-2 gene product (pl85) is required for growth inhibition by anti-pl85 antibodies but not for the cytotoxicity of an anti-pl85-ricin-a chain immunotoxin. Int J Cancer 1994;59:242–247.CrossRefPubMedGoogle Scholar
- 29.Brosh N, Eilat E, Zinger H, Mozes E: Characterization and role in experimental systemic lupus erythematosus of T-cell lines specific to peptides based on complementarity-determining region-1 and complementarity-determining region-3 of a pathogenic anti-DNA monoclonal antibody. Immunology 2000;99:257–265.CrossRefPubMedGoogle Scholar
- 34.Igarashi K, Asai K, Kaneda M, Umeda M, Inoue K: Specific binding of a synthetic peptide derived from an antibody complementarity determining region to phosphatidylserine. J Biochem (Tokyo) 1995;117:452–457.Google Scholar
- 37.Monnet C, Laune D, Laroche-Traineau J, Biard-Piechaczyk M, Briant L, Bes C, et al.: Synthetic peptides derived from the variable regions of an anti-cd4 monoclonal antibody bind to cd4 and inhibit hiv-I promoter activation in virus-infected cells. J Biol Chem 1999;274:3789–3796.CrossRefPubMedGoogle Scholar
- 48.Divita G, Restle T, Goody RS, Chermann JC, Baillon JG: Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J Biol Chem 1994;269: 13,080–13,083.Google Scholar
- 52.Cohen BD, Kiener PA, Green JM, Foy L, Fell HP, Zhang K: The relationship between human epidermal growth-like factor receptor expression and cellular transformation in nih3t3 cells. J Biol Chem 1996; 271:30,897–30,903.Google Scholar
- 57.Berezov A, Chen J, Liu Q, Zhang HT, Greene MI, Murali R: Disabling receptor ensembles with rationally designed interface peptidominetics. J Biol Chem 2002; 27:28,330–28,339.Google Scholar